novartis glp-1 receptor agonist Agonists: The New Wave in Diabetes Management Adverse Effects of GLP-1 Receptor
Description
Ethics declarations Competing Interests Financial interests: Jaewang Lee and Hyun Jin Park are employed by Logsynk Ltd
Since Wegovy's 2021 launch and Zepbound's approval five months ago, Novo Nordisk and Eli Lilly are leading the next generation of weight-loss drugs, targeting a market projected to reach $150bn by 2030
The American Diabetes Association's Standards of Care acknowledge the ongoing uncertainty, noting that while pancreatitis has been reported with GLP-1 receptor agonist use, a definitive causal relationship has not been established
It mimics GLP-1, a natural gut hormone, to regulate blood sugar, increase insulin, suppress appetite, and promote long-term weight loss
Like Ozempic and Rybelsus, it is designed to enhance blood sugar control in adults with type 2 diabetes
The glucagon-like peptide 1 analogue restores endothelial dysfunction, induces vasodilatation, and reduces plasma lipids
